Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India

Sandeep Nemani¹, Anu Korula¹, Bhumi Agrawal², M.L. Kavitha¹, Marie Therese Manipadam², Elanthenral Sigamani², Biju George¹, Alok Srivastava¹, Auro Viswabandya¹,² & Vikram Mathews¹

Departments of ¹Clinical Hematology & ²Pathology, Christian Medical College & Hospital, Vellore, India

Received July 9, 2016

Background & objectives: Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin’s lymphomas (NHLs), with universally poor outcome. This study was undertaken to provide data on demographics and outcomes of patients with PTCL who underwent treatment in a single tertiary care centre in southern India.

Methods: Retrospective study was done on all patients (age ≥18 yr) diagnosed with PTCL from January 2007 to December 2012. The diagnosis of PTCL was made according to the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Results: A total of 244 adult patients were diagnosed with PTCL (non-cutaneous). The most common subtype was PTCL-not otherwise specified (35.7%), followed by anaplastic large cell lymphoma (ALCL), ALK negative (21.3%), natural killer/T cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), ALCL, ALK positive, hepatosplenic T cell lymphoma (HSTCL) and adult T cell leukaemia/lymphoma followed in frequency with 13.1, 11.5, 8.6, 8.2 and 1.6 per cent cases, respectively. The three-year Kaplan-Meier overall survival (OS) and event-free survival (EFS) for the patients who received chemotherapy (n=122) were 33.8±5.0 and 29.3±4.7 per cent, respectively. Various prognostic indices developed for T cell lymphomas were found to be useful.

Interpretation & conclusions: Except for ALCL, ALK positive, all other PTCLs showed poor long-term outcome with CHOP-based chemotherapy. Novel therapies are needed to improve the outcome.

Key words: CHOP-based therapy - histological subtypes - non-cutaneous - non-Hodgkin lymphoma- overall survival - peripheral T cell lymphomas

Peripheral T cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin’s lymphomas (NHLs) which are of mature T cell origin¹, accounting for only 10-15 per cent of all lymphoid malignancies². A higher incidence has been described from Asia, especially natural killer T cell lymphoma (NKTCL) and adult T cell leukaemia, lymphoma (ATLL) subtypes².

¹Present address: Princess Margaret Cancer Centre, Toronto, Canada

© 2018 Indian Journal of Medical Research, published by Wolters Kluwer - Medknow for Director-General, Indian Council of Medical Research
The International Peripheral T Cell Lymphoma Project (IPTCLP) is the largest series describing pathological findings and outcomes in this group of patients. International Prognostic Index (IPI) was found to be useful for prognostication of PTCL, similar to that for B cell NHLs; however, certain PTCLs such as NKTCL are associated with poor outcome even with low IPI. Various new scoring systems, either subtype specific or non-specific with better risk stratification, have been compared; however, no single scoring system has been considered unanimously superior. CHOP-based regimens have shown poor results in T cell lymphomas, with the notable exception of anaplastic large cell lymphoma (ALCL), ALK positive. Molecular signatures by gene expression profiling have added to the understanding of these diverse groups of disorders. With advances in understanding of disease biology and development of newer treatment options, the outlook towards PTCL, which was referred to as 'poor step child' of lymphomas, is changing and the future seems to be hopeful for improved outcomes in this universally fatal group of disorders. The aim of the present study was to review the incidence of various PTCLs in a single centre from south India and to study the outcomes for the patients who underwent treatment from January 2007 to December 2012.

Material & Methods

All adult (age ≥18) patients diagnosed with PTCL (non-cutaneous) presenting to the Haematology department at Christian Medical College (CMC), Vellore, India, between January 2007 and December 2012 and whose data could be retrieved were included in this retrospective study. The study was approved by the Institutional Review Board. The diagnosis of PTCL was made in the department of Pathology, CMV, Vellore, according to the WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, Fourth Edition (2008). The immunohistochemistry markers used for diagnosis were CD3, CD4, CD8, ALK-1, CD56, CD30, EBV LMP-1, TIA-1, EMA, Ki-67, Granzyme B, CD43, CD138, CD20, PD-1, TDT, LCA, CD5, CD7, CD15, CD10, PAX-5, CD117, CD99 and CD21. T cell receptor clonality assay was performed in doubtful cases.

Results were analyzed in terms of the clinical characteristics and laboratory parameters at diagnosis and response to the different treatment regimens. Response to treatment was assessed by standard criteria. All patients started on treatment were evaluated for response and outcome. Overall survival (OS) was measured from the start of therapy up to the date of death (from any cause). For the purpose of this analysis, patients who had relapsed or had progressive disease during therapy and then subsequently lost to follow up or opted for palliative care were considered as dead, 30 days after the last follow up. Event-free survival (EFS) was calculated from the start of therapy up to the first adverse event, i.e. relapse, progression, secondary malignancy or death.

Descriptive statistics were calculated for all variables. Differences in proportions were assessed using the Chi-square test. Survival curves were drawn by the Kaplan-Meier method and compared by the log-rank test. SPSS 16.0 software (SPSS Inc., Chicago, IL, USA) was used for the analysis.

Results

Between January 2007 and December 2012, a total of 972 adult patients were diagnosed with NHLs, of whom 244 patients were diagnosed with PTCL (non-cutaneous) (25.1%). The most common subtype was PTCL-not otherwise specified (NOS) (n=83, 35.7%), followed by ALCL ALK negative (n=52, 21.3%). Others included NK-TCL (n=32, 13.2%), angioimmunoblastic T-cell lymphoma (AITL) (n=28, 11.5%), ALCL ALK positive (n=21, 8.6%), hepatosplenic T cell lymphoma (HSTCL) (n=20, 8.2%) and ATLL (n=4, 1.6%).

The clinical characteristics of all patients and those with different histological subtypes are shown in the Table. The median age was 45 yr (range 18-80 yr) with male predominance in all subtypes (n=202, 82.8%). The median age of patients with HSTCL and ALCL, ALK positive was found to be one decade earlier than the median age of the total patients. The majority of the patients had Stage III/IV disease except patients with NKTCL, where only 25 per cent cases (n=8) had advanced stage disease. Three patients had bone lesions. Bone marrow involvement was seen in 37.5 per cent (n=75 of 200) of cases and almost all patients with HSTCL (n=18, 90%) and ATLL (n=4, 100%) showed bone marrow involvement. Hemophagocytosis was seen in nine cases of 200 (4.5%). B symptoms and elevated LDH were also found in 81 (n=189 of 233) and 88 (n=177 of 199) per cent of patients, respectively. Median duration of symptoms before diagnosis was three months (range 1-48 months).

Autoimmune manifestations were seen in six patients (one had immune thrombocytopenia and five had autoimmune haemolyisis), all these patients had AITL. Hypergammaglobulinemia was found in five of 28 AITL patients (17.9%).
One hundred and twenty two of the total 244 patients proceeded with treatment at our centre. The distribution of all the patients is shown in Fig. 1. The majority of patients received CHOP-based chemotherapy (n=116, 95%). Sixty two per cent (n=76) of patients required admission during treatment for either febrile neutropenia or other chemotherapy-related side effects. The three-year Kaplan-Meier overall survival (OS) and EFS for the total patients on treatment (n=122) were 33.8±5.0 per cent (median follow up duration of 14 months) and 29.3±4.7 per cent (median follow up duration of 8 months), respectively (Fig. 2A and B). In the group of patients who completed therapy (n=64), the median follow up was 24 months (range 7-92 months). This group comprised 23 (35.9%) patients with ALCL and 23 (35.9%) patients with PTCL-NOS. The three-year Kaplan-Meier of OS and EFS for the PTCL-NOS (n=43), AITL (n=6), ALK-positive ALCL (n=18), ALK-negative ALCL (n=24), HSTCL (n=7), ATLL (n=3) and NK/T cell lymphoma (n=18) histological group were 27.4±7.8 and 62.5±21.3 per cent, 29.3±4.7 per cent (median follow up duration of 8 months), respectively (Fig. 2A and B).

Various prognostic scores were applied for risk stratification. In the case of NK/T cell lymphoma when the IPI was used as prognostic score, 57.1 per cent (n=18) of the cases were in lower risk categories (low and low intermediate), while 42.9 per cent (n=14) of the cases were in higher risk (high intermediate and high risk).

The three-year Kaplan-Meier OS and EFS for treated patients (n=116) when prognosticated by IPI score into low risk (n=25), low intermediate risk (n=20), high intermediate risk (n=50) and high risk (n=21) categories were 52.5±11.6 and 51.0±12.7 per cent, 27.8±7.2 and 6.9±6.6 per cent, 52.5±12.6 and 41.8±10.7 per cent, 22.5±6.7 and 8.2±7.6 per cent, respectively (Fig. 3A and B). The three-year Kaplan-Meier OS and EFS for treated patients (n=117) when prognosticated by PIT score into low risk (n=7), low intermediate risk (n=28), high intermediate risk (n=48) and high risk (n=34) categories were 63.3±21.0 and 51.1±10.4 per cent, 31.2±7.8 and 15.4±7.4 per cent, 57.1±18.7 and 40.3±10.0 per cent, 30.0±7.6 per cent versus 12.3±7.2 per cent, respectively (Fig. 4A and B).

**Discussion**

Although PTCL accounts for only 10 per cent of all NHL in the Western world, the incidence of T cell lymphomas is higher in Asia, with an incidence of 20 per cent noted in a recent retrospective study from India. As per the IPTCLP, PTCL-NOS was the most common subtype, followed by AITL (Western countries) and ATLL and NK/T cell lymphoma in Far Eastern countries. The most common histological subtype in our study was found to be PTCL-NOS (35.7%) followed by ALCL, ALK negative (21.3%). The median age of diagnosis was concordant with published literature for ALCL, ALK positive and HSTCL while the diagnosis was one decade earlier for rest of the subtypes.

Bony lesions were noted in only three patients (1.3%); however, bone marrow involvement was
seen in 37.5 per cent of patients. Data on specific extranodal sites involvement were not available in all cases. HSTCL had bone marrow involvement in 90 per cent of cases (n=18) and bone marrow involvement was least common with ALCL (ALK positive 0% and ALK negative 20%). This was comparable with published literature\(^2\). All patients with AITL, HSTCL and ATLL had Stage III/IV disease, whereas only 25 per cent cases of patients with NK/T cell lymphoma had Stage III/IV disease. The incidence of advanced stage disease was higher when compared to IPTCLP, possibly a reflection of differences in health-seeking behaviour.

Associated autoimmune manifestations in the form of autoimmune haemolytic anaemia and immune thrombocytopenia were found in six patients and all had a histological diagnosis of AITL. Hypergammaglobulinemia was found in 17.9 per cent of patients with AITL, compared with an earlier published study where it was seen in 30 per cent of cases\(^8\).

Prognostic scores such as IPI, IPTCLP score, PIT and mPIT when applied showed significantly poorer outcomes in high-risk groups\(^9-12\). In case of NK/T cell lymphoma when NKPI was used as a prognostic score, the majority of the patients (71.4%) were assigned to higher risk categories, compared to 42.9%.
per cent in the high-risk group when prognosticated by IPI. Considering the poor prognosis even with localized disease, NKPI is suggested to be used as a prognostic scoring system for this condition. Using PIAI as prognostic score for AITL, 84 per cent were in a high-risk category which was consistent with the previous study. In view of a small number of patients with AITL and NK/T cell lymphoma receiving treatment, survival difference depending on PIAI and NKPI could not be assessed in the present study.

Chemotherapy was administered to 122 patients, and majority received CHOP-based chemotherapy. Almost half of the patients required admission due to febrile neutropenia and other chemotherapy-related side effects. Growth factor support was used to augment neutrophil recovery in 59.3 per cent patients. Median follow up was only eight months. In view of only a few patients undergoing stem cell transplant, statistical correlation of the transplant data could not be done.

Our study showed the overall poor long-term outcome with CHOP-based chemotherapy in this group of patients (excluding ALCL, ALK positive), emphasizing the need for more intensive chemotherapeutic regimens. Median follow up duration was only eight months for the patients who were treated. In the group of patients who completed therapy (n=64), the median follow up was 24 months (range 7-92 months). This group comprised 23 (35.9%) patients with ALCL and 23 (35.9%) patients with PTCL-NOS. The OS and EFS of patients including all subgroups by IPI, PIT, mPIT and IPTCLP were significantly inferior in high-risk groups.

Even under ideal conditions, intensification of therapy has yielded only marginal benefits, with the exception of the addition of etoposide and possibly, autologous stem cell transplant. Recent advances in the treatment of relapsed PTCL have included the use of romidepsin and pralatrexate, but the addition of these agents to upfront therapy has not shown promising results.
PTCL is a diverse group of NHL with poor overall outcome compared to their B cell counterparts. Failure of CHOP-based chemotherapy warrants search for novel and affordable agents for treatment.

Financial support & sponsorship: None.

Conflicts of Interest: None.

References

1. Armitage JO. The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol 2013; 88 : 910-8.
2. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 2008; 26 : 4124-30.
3. Gutiérrez-García G, García-Herrera A, Cardesa T, Martínez A, Villamor N, Ghita G, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 2011; 22 : 397-404.
4. Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011; 153 : 451-85.
5. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
6. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 : 579-86.
7. Arora N, Manipadam MT, Nair S. Frequency and distribution of lymphoma types in a tertiary care hospital in South India: Analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. Leuk Lymphoma 2013; 54 : 1004-11.
8. Federico M, Rudiger T, Beller M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: Analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013; 31 : 240-6.
9. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24 : 612-8.
10. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329 : 987-94.
11. Gallamini A, Stelitano C, Calvi R, Beller M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103 : 2474-9.
12. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score. J Clin Oncol 2006; 24 : 2472-9.
13. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110 : 2316-23.
14. Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013; 119 : 371-9.
15. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group. Blood 2010; 116 : 3418-25.
16. d’Amore F, Relander T, Lauritzen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30 : 3093-9.
17. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of...
romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. *J Clin Oncol* 2012; 30: 631-6.

18. O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, *et al.* Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. *J Clin Oncol* 2011; 29: 1182-9.

19. Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, *et al.* A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Preliminary results from the T-cell consortium trial. *Blood* 2013; 122: 3034-44.

20. Dupuis J, Morschhauser F, Ghesquière H, Tilly H, Casasnovas O, Thieblemont C, *et al.* A phase Ib/II trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): The Ro-CHOP study. *Hematol Oncol* 2013; 31 (Suppl 1): 136-42.

*For correspondence:* Dr Anu Korula, Department of Clinical Hematology, Christian Medical College & Hospital, Vellore 632 004, Tamil Nadu, India
e-mail: anukorula@cmcvellore.ac.in